However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

Jim Cramer in a recent program on CNBC commented on Merck & Co Inc. (NYSE:MRK) earnings results and said the pharma giant’s ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country.

Despite indications that a single dose of Merck's (NYSE:MRK) human papillomavirus vaccine Gardasil could be as effective as ...

This downturn can be attributed to several factors: a lowered guidance for 2025 and growing concerns about the long-term ...

Merck issued guidance for 2025 that lags consensus amid struggles in China with Gardasil Merck's stock tumbled 11.8% Tuesday, putting it on track for its biggest one-day selloff in almost 17 years ...

Gardasil misses Q4 sales estimates Merck pulls Gardasil's long-term sales target Shares tumble 11% in early trading Feb 4 (Reuters) - Merck (MRK.N), opens new tab said on Tuesday it would not ship ...

Shares fell more than 10% as Merck paused Gardasil shipments to China, and 2025 sales guidance of $64.1 billion-$65.6 billion implies flat to 2% growth. Why it matters: HPV vaccine Gardasil has ...

In what’s shaping up to be a red-letter week for Gardasil, Merck & Co. has simultaneously opened a massive new manufacturing facility for the human papillomavirus (HPV) shot in the U.S. and put ...

March 11 (Reuters) - A federal judge ruled in favor of Merck (MRK.N), opens new tab in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers ...

A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers caused by the human papillomavirus and one of ...